Inflammatory mediators in MAS
The pathophysiology of meconium aspiration syndrome (MAS) is complex. Several mechanisms may be operative in the development of lung injury in MAS, including mechanical obstruction, 1 inactivation of surfactant, 2 pulmonary hypertension [3] [4] [5] [6] and lung inflammation. 7 Although the controversies still remain in the literature as to what extent meconium per se leads to MAS, 8, 9 increasing evidence indicates that the inflammation induced by meconium is an essential part of the pathophysiology. 7, 10 The assumed chemical pneumonitis caused by meconium was first documented in rabbits by infiltration of polymorphonuclear leukocytes in alveolar septa within 6 h after instillation of meconium, 11 and a later study documented increased counts and chemotactic activity of neutrophils in lung lavage fluid from pigs. 12 Leukocytes are important sources for three main inflammatory branches that are induced or activated by meconium: cytokines, arachidonic acid metabolites and reactive oxygen species.
In vitro meconium has been shown to trigger peritoneal macrophages to produce a proinflammatory tumor necrosis factor-a (TNF-a) response 13 and in animals instilled with human meconium interleukin (IL)-6, IL-8, TNF-a and IL-1b have been detected in cells harvested from lung lavage within 8 h after meconium instillation.
14 In another animal studies with the same observation time, TNF-a 15 and IL-8 have been detected in bronchoalveolar lavage fluid 16, 17 whereas IL-5 and IL-13 were elevated at day 7 in mice. 18 Furthermore, meconium may stimulate chemotaxis, the latter effect claimed to be because of IL-8 present in meconium. 19 Finally, the levels of IL-1b, IL-6, IL-8 and TNF-a have been compared in sterile meconium vs meconium contaminated with bacteria and in spite of variation among samples the median concentrations did not differ. 20 The transcription factor NF-kB, known to induce a number of proinflammatory cytokines, was shown to be activated by meconium in rat alveolar macrophages. 21 Human meconium is shown to contain phospholipase A 2 , thereby capable of directly damaging alveolar cells. 22 Meconium was found to increase the production of arachidonic acid metabolites by phospholipase A 2 23 and elevated catalytic activity of phospholipase A 2 was found both in tissue and lavage fluid. 24 In addition, meconium has been shown capable of upregulating cyclooxygenase-2 mRNA expression in rat lungs, a process that is inhibited by dexamethasone, but not indomethacin 25 and enhance the release of thromboxane-A 2 in human airway epithelial cells. 26 Finally, apoptosis associated with meconium 22, 27, 28 could be inhibited by angiotensin II receptor blockade. 27 The effect of meconium on oxidative burst (release of reactive oxygen species) has been difficult to interpret. Although one study showed that meconium stimulated alveolar macrophages to produce superoxide anion, 29 another study showed that light and very light meconium inhibited neutrophil oxidative burst. 30 Recently, it has been showed that meconium has an inhibitory effect on neutrophils in low concentrations (0.2 mg ml À1 ) but in higher concentrations (1 and 2 mg ml À1 ) stimulates neutrophil oxygen radical production progressively. 31 A possible role for complement in meconium-induced oxidative burst has been recently postulated (see below).
The complement system
Complement is one of the plasma cascade systems and represents a main part of fluid-phase innate immunity. 32 It consists of more than 30 proteins acting together in a specific manner with the principal function to protect the host against invading organisms. A simplified cartoon of the complement system is shown in Figure 1 . There are three initial pathways of activation.
The classical pathway (upper left) is activated either by natural or elicited antibodies binding to antigen, or by direct, antibody-independent activation, for example, by C-reactive protein. C1q triggers the serine proteases C1r and C1s, the latter cleaving C4 to C4b, which exposes a specific binding site for C2. C1s then cleaves C2 and the resulting C3 convertase C4b2a cleaves C3 to C3b to form the C5 convertase C4b2a3b. Splitting of C5 to the highly potent anaphylatoxin C5a and the C6-binding fragment C5b is the last enzymatic step in the cascade. Activation of the lectin pathway (upper middle) is initiated by mannose-binding lectin (MBL) recognizing mannose on bacteria, by immunoglobulin A and probably by structures exposed by damaged endothelium. MBL is homologous to C1q and triggers the MBL-associated serine proteases (MASPs), of which three forms (MASP1, MASP2 and MASP3) have been described. Further lectin pathway activation is virtually identical to classical pathway activation forming the same C3 and C5 convertases. The alternative pathway (upper right) activation differs from the classical and lectin pathways by a physiological, low-graded spontaneous hydrolysis of the internal thiol ester of the C3 molecule thereby binding factor B, which is then cleaved by factor D. The C3 convertase then formed cleaves C3 to C3a and C3b, the latter binds factor B forming C3bB, which is cleaved by factor D and the alternative pathway C3 convertase, C3bBb, is formed leading to further cleavage of C3. C5 is then activated in the same manner as for the classical and lectin pathway C5 convertase.
Thus, all three pathways converge at C3 and the terminal pathway (lower part of Figure 1 ) proceeds in the same way irrespective of the initial pathway activation, by assembly of C7 to C5b-6, forming an amphiphilic complex able to insert into a lipid membrane. One C5b-7 moiety binds one C8 and one or several C9 molecules, creating a physical pore penetrating the membrane (C5b-9(m) or membrane attack complex, leading to transmembrane leakage and subsequent cell activation, or more infrequently to lysis (lower right). If the activation occurs in the fluid phase and there is no membrane present, the C5b-7 complex binds to vitronectin and clusterin (fluid-phase regulators of the terminal pathway) and thus retains hydrophilic properties. Final assembly of a soluble C5b-9 (SC5b-9), the second form of the terminal complement complex (TCC), occurs by binding of C8 and C9. Soluble TCC is a particularly useful indicator of complement activation and an assay for use in humans, baboons and pigs has been developed. 33 Complement activation is strictly regulated by inhibitory proteins of which some are illustrated in Figure 1 (boxes with broken lines). The biological potency of this system is substantial and when activated out of control it may break down essential homeostatic mechanisms, for example, as seen in irreversible septic shock. 34 Thus, it is crucially important to keep the system under control by the regulatory proteins. C1 inhibitor regulates the initial classical and lectin pathways. Carboxypeptidase N inactivates the anaphylatoxins C5a, C3a and C4a, of which C5a is particularly potent. Factor I cleaves and inactivates C4b and C3b and uses C4b-binding protein (C4BP) as cofactor in the classical/lectin pathway and factor H in the alternative pathway. The membrane regulators complement receptor 1 (CR1; CD35), membrane cofactor protein (MCP; CD46) and decay-accelerating factor (DAF; CD55) regulate complement activation by either acting as cofactors for factor I-mediated cleavage of C4b and C3b (CR1 and MCP), or accelerating the decay of the biomolecular C3 and C5 convertases (CR1 and DAF). CD59, also a membrane regulator, prevents the binding of C9 to the C5b-8 complex in the terminal pathway.
The main biological effect of complement activation is induction of an inflammatory reaction. Many of the activation products are involved in this process, but C5a is particularly important. Innumerable inflammatory mediators are induced by C5a, when it reacts with its receptor (C5aR). Most of the inflammatory branches can be triggered by C5a (Figure 2 ), illustrating that complement has a key function as an upstream mediator of a broad spectrum of inflammatory reactions. Thus, activated complement is a double-edged sword with undesired effects in many conditions. Various reagents with potential Figure 1 Schematic illustration of the complement system. Activation may occur through three initial routes: the classical, the lectin and the alterative pathways. All three pathways converge at the level of C3 and proceed through the terminal pathway. Biologic active fragments are released when native components are activated, like the potent anaphylatoxin C5a when C5 is cleaved. To keep the system under strict control, a number of inhibitor and regulatory proteins are present, as illustrated with dotted boxes and lines. therapeutic applications have been recently developed to target complement activation and function. 35 
MAS and the complement system
In the first study of a possible interaction of complement and MAS it was documented that meconium in vitro is a highly potent activator of the complement system. 36 Adding meconium to human umbilical serum induced a substantial increase in TCC formation, which was found to be mediated mainly through the alternative activation pathway. As judged by their relative amounts in whole meconium, the lipid and water fractions contributed equally to this activation. However, corrected for the lower amount of the lipid fractions compared with the water fractions in normal meconium, the lipid fraction per weight was more potent.
In a whole-blood model established for studying the interaction of the complement system with the inflammatory network, 37 we studied the role of complement in meconium-induced leukocyte activation as measured by oxidative burst and expression of the surface activation markers CD11b and L-selectin. 38 Meconium induced a marked oxidative burst that was reduced by 60 to 70% when adding the alternative complement pathway inhibitor anti-factor D. Furthermore, meconium induced a substantial increase in CD11b and decrease in L-selectin, typical for leukocyte activation, which was virtually abolished (95 to 100%) by adding anti-factor D. Importantly, inhibition of complement using a specific C5aR antagonist gave the same inhibition of both oxidative burst and expression of CD11b and L-selectin as anti-factor D, implying that C5a was solely responsible for the meconium-induced complement-dependent leukocyte activation.
On the basis of these in vitro experiments we proceeded with in vivo studies using a well-established piglet model of MAS. 39 Here we demonstrated that complement is activated systemically, as detected by a substantial increase in plasma TCC. The increase in TCC correlated positively with oxygenation and ventilatory indexes and negatively with lung compliance. Finally, the mortality of the piglets correlated with the increase in TCC, indicating that the breakdown in homeostatic mechanisms may be associated with uncontrolled complement activation. These observations led us to further investigate the role of complement in experimental MAS. 40 In this study we found that experimental MAS piglets reflected an inflammatory response, measured by cytokines and complement, closely resembling the systemic inflammatory response syndrome (SIRS). We therefore propose that MAS is associated with a general whole-body SIRS-like inflammatory reaction. It remains, however, to be shown whether complement activation actually contributes to the pathophysiology of clinical MAS and if inhibition of complement may attenuate inflammation and severity in MAS. Lately, we have focused our research on the two main branches of innate immunity: the fluid-phase complement system and the cellular Toll-like receptor (TLR) system, the latter with focus on the CD14/MD2/TLR4 pathway. Thus, we studied the effect of meconium on these two branches as well as the effect of specific inhibition of both complement and CD14. Interestingly, we found that inhibition of both pathways efficiently attenuated the inflammatory reaction induced by meconium (B Salvesen et al., manuscript submitted).
Addendum
To the best of our knowledge we are the first and so far the only group that has studied the interaction between complement and MAS. How comes that these studies were initiated? The answer is simple: an incidental meeting in a PhD dissertation a few years ago by two scientists (first and last authors of this paper), one an expert on complement and the other on MASFboth of them at that time virtually devoid of knowledge on the other's research fieldFled to an interesting discussion. First author asked: 'what is at present your main research'? After getting the answer he replied 'what is really MAS'? Having got a brief introduction to MAS, the last author asked: 'but what is your main focus'? After answering, last author replied: 'but what is actually complement'? Two completely different scientific worlds met and recognized that we had to proceed on a novel trackFdoes meconium as such activate the complement system and is complement activated in experimental MAS? As there were no reports of this topic in the literature we initiated studies by mutually utilizing well-established models to study complement activation and MAS, respectively. Lessons to learn are that scientific groups to a greater extent should discuss possible interacting mechanisms of pathophysiology when they meet, and we should all accept that homeostasis in human biology is more complex than seen just from our own window, consequently leading to collaboration to obtain scientific progress. 
